Tumor

LDH, one of the earliest marker still being used along with troponins in the diagnosis of acute myocardial infarction is now emerging as an important marker in a wide range of cancers. Recently LDH and its isoenzymes have been extensively studied in the detection and its prognostic role in common tumors such as colorectal, breast, ovarian, prostate, liver and various other metastases. LDH levels have been correlated with CEA, CA 15.3, CA 125,CA19.9 and Hodgkin’s lymphomas. Further, isoenzymes of LDH are being studied extensively and each isoenzyme was found to be specific for a particular cancer. LDH has been linked to intracellular enzymes through damaged cells in apotoposis and deregulation. Studies suggest that inhibiting LDH activity may lead to possible anticancer treatment. The objective of this review article is to present the outcome of various research findings during the last two decades and to make awareness among research scholars to undertake further research to establish the exact clinical role of LDH in each type of cancer.

Progress in the diagnosis and treatment of neoplasm in children in past few decades is one of the most gratifying achievement in the field of oncology. Childhood lymphomas are rare paediatric malignancy characterized by abnormal growth of lymphocytes. Aims and Objectives of this study was to describe the epidemiology of childhood cancer in western Uttar Pradesh, a state in Northern India, that would serve as a National reference source and will act as a seminal to spawn new research in the field of childhood lymphomas. The study evaluated a total of 252 cases of pediatric tumors over a period of seven years, including patient of 0-12 years of age group; attending the out-patients and in-patients of Jawaharlal Nehru Medical College (tertiary care centre), Aligarh, with the complaints of tumor associated sign and symptomsLymphoma being 3rd most common childhood malignancy in our study comprised a total of 15 cases, that included 9 cases of Hodgkin’s Lymphoma (HL) and 6 cases of Non Hodgkin’s Lymphoma (NHL). It accounted for 6% of total neoplasm and 12.5% of all pediatric malignancies. The mean age of occurrence was 8.1 years with a slight male predilection.